Hepatitis C Articles (HCV)
Back
	GT1-5 Sofosbuvir/Harvoni / GS5816 / GS9857 Future Pangenotypic Protease Inhibitor       EASL: Ledipasvir/Sofosbuvir for the Treatment of Patients With Chronic Genotype 4 or 5 HCV Infection - (04/29/15)   GS-5816 2nd Gen NS5A - Pangenotypic Gilead Protease Inhibitor   GS-9857 Pangenotypic Protease Inhibitor + SOF/GS5816 for 6/8 Weeks..... EASL: SAFETY AND EFFICACY OF SHORT-DURATION TREATMENT WITH GS-9857 COMBINED WITH SOFOSBUVIR/GS-5816 IN TREATMENT-NAIVE AND DAA-EXPERIENCED GENOTYPE 1 PATIENTS WITH AND WITHOUT CIRRHOSIS - (04/23/15)   EASL: Gilead Announces Data for Investigational, All-Oral, Pan-Genotypic Three-Drug Regimen of Sofosbuvir, GS-5816 and GS-9857 for Chronic Hepatitis C - (04/24/15)   EASL: Evaluation of the Pangenotypic HCV NS3/4A Protease Inhibitor GS-9857 in Healthy Volunteers - (04/29/15)   EASL: Preclinical Profile of the Pangenotypic HCV NS3/4A Protease Inhibitor GS-9857 - (04/29/15)   EASL: Resistance Analysis of Treatment-Experienced Genotype 1 and 3 HCV-Infected Patients Treated With Sofosbuvir in Combination With GS-5816 ± Ribavirin for 12 Weeks - (05/04/15)   Future Phase 3 study - Gt1-6 EASL: The ASTRAL Studies: Evaluation of SOF/GS-5816 Single-Tablet Regimen for the Treatment of Genotype 1-6 HCV Infection - (05/04/15)   GT2 Sovaldi/Rbv EASL: 98% SVR12 in Korean and Taiwanese Patients With Chronic Genotype 2 HCV Infection Receiving 12 Weeks of Sofosbuvir Plus Ribavirin: Results From an International, Multicenter Phase 3 Study - (04/31/15)   Harvoni in Japan GT1 EASL: 100% SVR12 With Ledipasvir/Sofosbuvir ± Ribavirin for 12 Weeks in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Who Previously Failed Protease Inhibitor + Pegylated Interferon-a + Ribavirin Therapy - (04/31/15)           View Older Articles   Back to Top   www.natap.org